Key Highlights

  • Motus GI Holdings closed the session with shares up 100% to $0.0002, a move that came entirely from a single one-cent-fraction tick off a $0.0001 base rather than any fresh trading momentum.
  • The company's Pure-Vu System, an FDA-cleared device for improving colonoscopy visualization, remains its core asset even as regular financial filings have lapsed since mid-2024.
  • Full-year 2023 figures show Revenue near $319,000, down about 46% year over year, alongside a net loss of roughly $12.9 million.
  • With a market Capitalization of only about $1,400, MOTS trades as a distressed over-the-counter name where even negligible Volume can move the quoted price by large percentages.

Motus GI Holdings (OTC:MOTS) drew notice at the close for a 100% single-session gain, but the arithmetic behind that number is less dramatic than the headline figure suggests. Shares moved from $0.0001 to $0.0002, a rise of exactly one hundredth of a cent, on a sub-penny stock where any uptick at all produces an outsized percentage. Once listed on Nasdaq, the company has since faded to over-the-counter trading at fractional pricing, with a Market Value now sitting near $1,400.

Company and Latest Development

Motus GI developed the Pure-Vu System, a device cleared by the FDA to improve visualization during colonoscopy by cleansing the colon in real time. The company was previously listed on Nasdaq but now trades over the counter at sub-penny prices.

Its most substantive public filings date to mid-2024, and its history includes earlier milestones such as positive results reported from a European study of a second-generation Pure-Vu System, Warrant exercises that raised gross proceeds, and a U.S. Patent covering a self-purging feature.

What's Behind the Move

The 100% change reflects the mechanics of sub-penny quoting rather than a disclosed development. At a $0.0001 share price, the smallest possible uptick to $0.0002 registers as a 100% gain even on negligible volume, and no clearly identifiable public catalyst accompanies the move.

Swings of this size are routine in distressed OTC names and typically point to thin Liquidity and wide spreads rather than a change in the underlying business.

Key Numbers and Company Position

Aggregated data describe a company under considerable financial strain. Revenue came in near $319,000 for 2023, down about 46% from the prior year, alongside a net loss of approximately $12.9 million for that year. Market capitalization stands at roughly $1,400 based on the $0.0002 quote.

The absence of regular filings since mid-2024 limits outside visibility into current operations, cash position, and any ongoing commercial activity, so snapshot figures should be treated as indicative rather than confirmed.

What Could Come Next?

Meaningful developments from here would likely be structural in nature: a resumption of regular SEC or OTC Markets reporting, a reverse merger, an asset or intellectual-property sale, new financing, or a formal wind-down. Any of these would surface through filings or OTC disclosure.

Absent such news, trading is likely to continue reflecting sentiment and micro-cap speculation rather than operational progress.

Risks to Watch

The risks facing sub-penny OTC stocks like this one are severe and, in some cases, existential. Extreme volatility, very wide bid-ask spreads, and a heightened risk of total loss are all characteristic of this trading tier.

The lapse in recent filings raises questions about whether the company remains actively operating and reporting, and deregistration is a real possibility for issuers that fall behind. Any future capital raise could prove heavily dilutive, and liquidity can disappear without warning, leaving holders unable to exit at the quoted price.

A Delisted Device Maker Trading on Fractions of a Cent

Motus GI Holdings illustrates how a striking percentage figure can obscure a much smaller underlying reality. A move from one hundredth of a cent to two hundredths is a single price tick, not a momentum shift, and no verified catalyst supports the headline framing.

What remains durable is the picture of a formerly Nasdaq-listed medical-device company now trading over the counter at a market value near $1,400, with filings that have gone quiet since mid-2024. Renewed disclosure or a corporate action would be the signals worth watching for, while the sub-penny trading itself continues to reflect liquidity mechanics more than fundamentals.